Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize recent clinical data on the safety and efficacy of next-generation NNRTIs
- Describe the impact of NNRTI resistance mutations on response to both currently FDA-approved NNRTIs and next-generation NNRTIs
- Discuss the use of investigational or recently approved agents in combination with currently approved therapies to maximize outcomes in treatment-experienced HIV-infected patients
CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.